Longevity regulation is shifting, but barriers remain
The US Food and Drug Administration has publicly named aging a priority. At the same time, the regulatory framework for treatments that target the aging process itself remains underdeveloped.
At a recent scientific congress on aging and drug discovery (ARDD) in Boston, senior FDA officials spoke about longevity as a policy theme. The researchers and policymakers present describe a noticeable shift in tone. The discussion moved away from whether aging is a disease and toward what approval routes should look like for treatments that target the biology of aging.
What is concretely changing
The discussion centred on three tools that already exist in other medical domains: platform technology designations, validated stand-in measures, and iterative development models. Stand-in measures are biological values that can be tested and measured as a substitute for a real-world health outcome, such as lower blood pressure as a sign of fewer heart attacks. For aging treatments, such measures have not yet been officially established. This makes it difficult to demonstrate that a treatment works, even if it may.
Barriers are increasingly institutional
According to the authors of the accompanying position paper, the main obstacles are no longer purely scientific but also institutional. They argue that extending existing regulatory tools to cover treatments targeting multiple age-related conditions simultaneously is the most viable path forward. This is an opinion piece and commentary from the Longevity Research Institute, not a clinical study.
Search terms to explore further: stand-in measures for aging research, approval routes for longevity treatments, FDA drug approval aging biology